A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

NCT04786028 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

OTHER: Isatuximab

Sponsor

Canadian Myeloma Research Group